A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia

References

• Deschler B, Lubbert M, Deschler B, et al. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099–2107.
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003;16:1091–1110.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010:56–61.
   PubMed Web of Science ®Google Scholar
• Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302–314.
   PubMed Web of Science ®Google Scholar
• Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin Oncol 2006;33(Suppl. 8):S22–S27.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710–717.
   PubMed Web of Science ®Google Scholar
• Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001;28(Suppl. 12):2–7.
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Lowenberg B, et al. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487–494.
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A, Robak T, et al. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009;31:2349–2370.
   PubMed Web of Science ®Google Scholar
• Johnson C. Cardiac toxicity: view of a cardiologist. Paper presented at First Annual Canadian Cardiac Oncology Network Conference, 18 September 2011, Ottawa, ON, Canada.
   Google Scholar
• Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 2008;42:99–104.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Cancer Netw 2012;10:984–1021.
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686–1744.
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146–1162.
   PubMed Web of Science ®Google Scholar
• De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996;39:504–512.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815.
   PubMed Web of Science ®Google Scholar
• Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92–98.
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62–69.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159–3165.
   PubMed Web of Science ®Google Scholar
• Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864–1871.
   PubMed Web of Science ®Google Scholar
• British Committee for Standards in Haematology, Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006;135:450–474.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Appelbaum FR, Baer MR, et al. Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Cancer Netw Jan 2006;4:16–36.
   PubMedGoogle Scholar
• Menna P, Paz OG, Chello M, et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012;1(Suppl. 1):S21–S36.
   Web of Science ®Google Scholar
• Crivellari D, Lombardi D, Spazzapan S, et al. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 2004;49s:153–163.
   Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Porea TJ, Dreyer ZE, Bricker JT, et al. Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol 2001;23:420–423.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition. Am J Clin Oncol 2001;24:425–428.
   PubMed Web of Science ®Google Scholar
• Conrad AL, Gundrum JD, McHugh VL, et al. Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma. J Oncol Pract 2012;8:336–340.
   PubMedGoogle Scholar
• Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009;113:28–36.
   PubMed Web of Science ®Google Scholar
• Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 2013;121: 2618–2626.
   PubMed Web of Science ®Google Scholar
• Greep JM, Siezenis LM. Methods of decision analysis: protocols, decision trees, and algorithms in medicine. World J Surg 1989;13: 240–244.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Offidani M, et al. Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). J Antimicrob Chemother 2010;65:2013–2018.
   PubMed Web of Science ®Google Scholar
• Poirier L, Drouin D.[Knowledge transfer and implementation of clinical practice guidelines. Experience of the Canadian Hypertension Education Program]. Nephrol Ther 2009;5(Suppl. 4):S246–S249.
   PubMed Web of Science ®Google Scholar
• Sharma DC, Sharma DC. Standard protocol helps improve ALL survival rates in India. Lancet Oncol 2002;3:710.
   PubMed Web of Science ®Google Scholar
• Shibata MC, Nilsson C, Hervas-Malo M, et al. Economic implications of treatment guidelines for congestive heart failure. Can J Cardiol 2005;21:1301–1306.
   PubMed Web of Science ®Google Scholar
• Woolf SH. Practice guidelines: a new reality in medicine. I. Recent developments. Arch Intern Med 1990;150:1811–1818.
   PubMed Web of Science ®Google Scholar
• Cancer incidence in Canada 2007 and 2008. Ottawa: Statistics Canada; 2010. pp 24–25.
   Google Scholar
• Canadian cancer statstics 2010. Toronto: Canadian Cancer Society; 2010.
   Google Scholar
• Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978;65:823–832.
   PubMed Web of Science ®Google Scholar
• Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. Ann Oncol 2001;12:963–966.
   PubMed Web of Science ®Google Scholar
• Hayek ER, Speakman E, Rehmus E, et al. Acute doxorubicin cardiotoxicity. N Engl J Med 2005;352:2456–2457.
   Google Scholar
• Volkova M, Russell R 3rd, Volkova M, et al. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7:214–220.
   PubMedGoogle Scholar